# OnCo record savolitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/savolitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "savolitinib" ;
  schema:name "Savolitinib"@en ;
  schema:description "Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib."@en ;
  schema:url <https://onco.cc/drugs/savolitinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Savolitinib> ;
  schema:citation <https://www.hutch-med.com/>, <https://www.astrazeneca.com/media-centre/press-releases.html>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule selective MET TKI" ;
  schema:alternateName "Orpathys" ;
  onco:approval "China 2021: MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full)", "China 2025: With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/papillary-rcc/>, <https://onco.cc/cancers/met-altered-nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/>, <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/hutchmed/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/nct05009836/>, <https://onco.cc/trials/nct05043090/>, <https://onco.cc/trials/nct04606771/>, <https://onco.cc/trials/nct03944772/>, <https://onco.cc/trials/nct03091192/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/trials/nct05261399/>, <https://onco.cc/trials/nct05374603/> ;
  onco:people <https://onco.cc/people/su-weiguo/> .